AU2001269876A1 - Heteroarylalkanoic acids as integrin receptor antagonists - Google Patents

Heteroarylalkanoic acids as integrin receptor antagonists

Info

Publication number
AU2001269876A1
AU2001269876A1 AU2001269876A AU6987601A AU2001269876A1 AU 2001269876 A1 AU2001269876 A1 AU 2001269876A1 AU 2001269876 A AU2001269876 A AU 2001269876A AU 6987601 A AU6987601 A AU 6987601A AU 2001269876 A1 AU2001269876 A1 AU 2001269876A1
Authority
AU
Australia
Prior art keywords
receptor antagonists
integrin receptor
heteroarylalkanoic
acids
heteroarylalkanoic acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001269876A
Inventor
Mark Laurence Boys
Nizal Samuel Chandrakumar
Barbara Chen
Balekudru Devadas
Ish Kumar Khanna
Hwang-Fun Lu
Scott B. Mohler
Scrinivasan Raj Nagarajan
Thomas D Penning
Mark Russell
Lori A. Schretzman
Dale P. Spangler
Michael B. Tollefson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of AU2001269876A1 publication Critical patent/AU2001269876A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
AU2001269876A 2000-06-15 2001-06-15 Heteroarylalkanoic acids as integrin receptor antagonists Abandoned AU2001269876A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21178100P 2000-06-15 2000-06-15
US21178200P 2000-06-15 2000-06-15
US60/211,782 2000-06-15
US60/211,781 2000-06-15
PCT/US2001/019375 WO2001096334A2 (en) 2000-06-15 2001-06-15 Heteroarylalkanoic acids as integrin receptor antagonists

Publications (1)

Publication Number Publication Date
AU2001269876A1 true AU2001269876A1 (en) 2001-12-24

Family

ID=26906455

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001269876A Abandoned AU2001269876A1 (en) 2000-06-15 2001-06-15 Heteroarylalkanoic acids as integrin receptor antagonists

Country Status (7)

Country Link
US (2) US7119098B2 (en)
EP (1) EP1289983A2 (en)
JP (1) JP2004511434A (en)
AR (1) AR031109A1 (en)
AU (1) AU2001269876A1 (en)
PE (1) PE20020382A1 (en)
WO (1) WO2001096334A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001096334A2 (en) * 2000-06-15 2001-12-20 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
DE60236418D1 (en) 2001-03-19 2010-07-01 Dainippon Sumitomo Pharma Co ARYLSUBSTITUTED ALICYCLIC COMPOUND AND MEDICAL COMPOSITION CONTAINING THEREOF
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
AU2003297409A1 (en) * 2002-12-20 2004-07-22 Pharmacia Corporation Pyrazole compounds as integrin receptor antagonists derivatives
EP1572690A1 (en) * 2002-12-20 2005-09-14 Pharmacia Corporation Thiazole compounds as integrin receptor antagonists derivatives
BR0317600A (en) * 2002-12-20 2005-11-29 Pharmacia Corp heteroarylalkanoic acids as derivatives of integrin receptor antagonists
US7351711B2 (en) 2003-07-31 2008-04-01 Janssen Pharmaceutical, N.V. Tricyclic indanyls as integrin inhibitors
US20080306116A1 (en) * 2007-06-08 2008-12-11 Christ Andreas D Aryloxazole, aryloxadiazole and benzimidazole derivatives
WO2010023609A1 (en) * 2008-08-25 2010-03-04 Piramal Life Sciences Limited Oxazole, oxadiazole and thiazole derivatives as diacylglycerol acyltranferase inhibitors
KR20120027265A (en) 2009-04-27 2012-03-21 다우 아그로사이언시즈 엘엘씨 Insecticidal pyridine compounds
JP5791150B2 (en) * 2009-12-15 2015-10-07 塩野義製薬株式会社 Oxadiazole derivatives having vascular endothelial lipase inhibitory activity
WO2011112828A1 (en) 2010-03-12 2011-09-15 Omeros Corporation Pde10 inhibitors and related compositions and methods
JP6215324B2 (en) 2012-07-18 2017-10-18 セントルイス ユニバーシティ Beta amino acid derivatives as integrin antagonists
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2016172573A1 (en) 2015-04-24 2016-10-27 Omeros Corporation Pde10 inhibitors and related compositions and methods
CA3003611C (en) 2015-11-04 2022-11-01 Omeros Corporation Solid state forms of a pde10 inhibitor
KR20180107121A (en) 2015-12-30 2018-10-01 세인트 루이스 유니버시티 Meta-azacyclic aminobenzoic acid derivatives as pan integrin antagonists
GB201604680D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
KR102510858B1 (en) * 2016-11-08 2023-03-15 브리스톨-마이어스 스큅 컴퍼니 Azolamides and amines as alpha V integrin inhibitors
CA3045491A1 (en) 2016-12-29 2018-07-19 Indalo Therapeutics, Inc. Integrin antagonists
EP4147698A1 (en) 2017-02-28 2023-03-15 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
RU2022108080A (en) 2017-02-28 2022-04-07 Морфик Терапьютик, Инк. INTEGRIN AVB6 INHIBITORS
RU2758373C2 (en) 2017-05-22 2021-10-28 Топадур Фарма Аг New activators of soluble guanylate cyclase and phosphodiesterase inhibitors with dual action mechanism and their application
CN112135612A (en) * 2018-03-07 2020-12-25 普利安特治疗公司 Amino acid compounds and methods of use
TW202035400A (en) 2018-08-29 2020-10-01 美商莫菲克醫療股份有限公司 Inhibiting αvβ6 integrin
CN109369530B (en) * 2018-11-15 2022-03-04 河北三川化工有限公司 Preparation method of 2, 4-dioxo-3-aza-spiro [5,5] undecane-1, 5-dinitrile
EP4054608A4 (en) * 2019-11-06 2024-02-21 Albert Einstein College Of Medicine Small molecule prostagladin transport inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9023289D0 (en) 1990-10-25 1990-12-05 Ici Plc Herbicides
EP0667773A4 (en) 1992-10-14 1996-09-25 Merck & Co Inc Fibrinogen receptor antagonists.
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
WO1997036860A1 (en) * 1996-03-29 1997-10-09 G.D. Searle & Co. Cinnamic acid derivatives and their use as integrin antagonists
WO1997036862A1 (en) * 1996-03-29 1997-10-09 G.D. Searle & Co. META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS
DE19620041A1 (en) * 1996-05-17 1998-01-29 Merck Patent Gmbh Adhesion receptor antagonists
JP2001524481A (en) * 1997-11-26 2001-12-04 デュポン ファーマシューティカルズ カンパニー 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as αVβ3 antagonists
WO1999030709A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
JP2002508326A (en) 1997-12-17 2002-03-19 メルク エンド カムパニー インコーポレーテッド Integrin receptor antagonist
BR9912638A (en) 1998-08-07 2001-05-02 Smithkline Beecham Corp Vitronectin receptor antagonists
HUP0302468A2 (en) 1999-06-02 2003-11-28 Merck & Co., Inc. Alpha v integrin receptor antagonists and pharmaceutical compositions containing them
CA2386030A1 (en) 1999-10-04 2001-04-12 Merck & Co., Inc. Integrin receptor antagonists
WO2001096334A2 (en) 2000-06-15 2001-12-20 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists

Also Published As

Publication number Publication date
US20020133023A1 (en) 2002-09-19
PE20020382A1 (en) 2002-05-10
WO2001096334A2 (en) 2001-12-20
US6933304B2 (en) 2005-08-23
JP2004511434A (en) 2004-04-15
US20040092497A1 (en) 2004-05-13
EP1289983A2 (en) 2003-03-12
WO2001096334A3 (en) 2002-09-12
AR031109A1 (en) 2003-09-10
US7119098B2 (en) 2006-10-10

Similar Documents

Publication Publication Date Title
AU2001269876A1 (en) Heteroarylalkanoic acids as integrin receptor antagonists
AU2003299807A1 (en) Heteroarylalkanoic acids as integrin receptor antagonists
AU2002210782A1 (en) Amide derivatives as nmda receptor antagonists
AU2001269821A1 (en) Cycloalkyl alkanoic acids as integrin receptor antagonists
AU7315800A (en) Mch antagonists
AU2001250205A1 (en) Prostaglandin d2 receptor antagonists
EP1194151A4 (en) Integrin receptor antagonists
AU2001234741A1 (en) Integrin antagonists
AU2001264657A1 (en) Crf receptor antagonists
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
AU2001231730A1 (en) Piperidyl carboxylic acids as integrin antagonists
AU2001290772A1 (en) Alpha v integrin receptor antagonists
AU2541000A (en) Beta-phenylalanine derivatives as integrin antagonists
AU2441801A (en) Urotensin-ii receptor antagonists
AU6990000A (en) Novel integrin receptor antagonists
AU2001286409A1 (en) N-methyl-d-aspartate receptor antagonists
AU2002220598A1 (en) Beta-amino acid derivatives as integrin receptor antagonists
AU2001240021A1 (en) Diazafluorenone il-8 receptor antagonists
AU2001245724A1 (en) Il-8 receptor antagonists
AU2001250820A1 (en) Novel cyclohexene derivatives useful as antagonists of the motilin receptor
AU6221201A (en) Propanoic acid derivatives as integrin receptor antagonists
AU2002226048A1 (en) Urotensin-ii receptor antagonists
AU2002216079A1 (en) Bombesin receptor antagonists
AU2001243351A1 (en) Il-8 receptor antagonists
AU2002239506A1 (en) Urotensin-ii receptor antagonists